Athernal Bio
Targeted immunotherapies aim to stop blood cancers by treating high-risk clonal hematopoiesis before malignancy emerges.
~£700KGrant
ParticipantIU
Innovate UK
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jul 27, 2026
Innovate UK is the innovation agency identified as a grant backer by Respiro Diagnostics and through its Investor Partnerships Programme by Adaptavate.
Recorded funding activity
Adaptavate develops lower-carbon building materials. Other recorded companies include Productive Machines’ CNC setup software and Athernal’s targeted therapies for high-risk blood conditions. Grant and investment-program participation must retain the instrument stated in each announcement.
Sources
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- — 0 disclosed · full round size, not this investor’s share